Cite
HARVARD Citation
Schmidinger, M. et al. (n.d.). Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR). European journal of cancer. pp. S187-S188. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Schmidinger, M. et al. (n.d.). Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR). European journal of cancer. pp. S187-S188. [Online].